Mirati Therapeutics Inc

NASDAQ:MRTX   3:59:57 PM EDT
69.73
+1.57 (+2.30%)
Earnings Announcements

Mirati Therapeutics Says Adagrasib Delivers Positive Results In Registration-Enabling Study Of Patients With Krasg12c-Mutated Advanced Non-Small Cell Lung Cancer

Published: 05/26/2022 21:47 GMT
Mirati Therapeutics Inc (MRTX) - Mirati Therapeutics - Adagrasib Delivers Positive Results in Registration-enabling Study of Patients With Krasg12c-mutated Advanced Non-small Cell Lung Cancer.
Mirati Therapeutics - of Patients Evaluable for Response From Adagrasib Study, Results Showed Disease Control Rate Was 80%.
Mirati Therapeutics - of Patients Evaluable for Response From Adagrasib Study, Results Showed Orr by Blinded Independent Central Review Was 43%.
Mirati Therapeutics - of Patients Evaluable for Response From Adagrasib Study, Results Showed Median Duration of Response Was 8.5 Months.
Mirati Therapeutics - As of Oct 15, 2021 Results From Pooled Analysis of Krystal-1 Nsclc Cohorts Showed Orr of 44%, Disease Control Rate of 81%.
Mirati Therapeutics - Safety Profile of Adagrasib in Study Was Consistent With Prior Reports and No New Safety Signals Were Observed.
Mirati Therapeutics - Safety, Tolerability Profile of Krystal-1 Nsclc Cohorts Consistent With Findings for Adagrasib in Patients With Advanced Nsclc.
Further Company Coverage: Mrtxo ((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $0.38 Million
Adjusted EPS is expected to be -$3.49

Next Quarter Revenue Guidance is expected to be $3.31 Million
Next Quarter EPS Guidance is expected to be -$3.61

More details on our Analysts Page.